This year has seen more than its share of successful IPOs – and some giant flops. The extremes should have been expected, in …
In a previous article, I talked about the so-called patent cliff and the correlation to the pace of mergers and acquisitions in the pharma …
Black Friday is past. So is Cyber Monday.
By Genia Turanova There’s nothing like cash to show how successful a company has been. When a fledgling enterprise first turns cash-flow positive …
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) just riled up Wall Street today with enticing Phase 2 study results in non-small cell lung cancer (NSCLC), sending …
Raymond James’ Reni Benjamin may scale back his expectations on INCY, but still bets on 24% in return potential for shares.
Mizuho’s Irina Rivkind Koffler has gotten more upbeat on the VRX name, but her raised expectations watch for 6% in loss potential for the stock.
With SCPH standing before the FDA this summer and RIGL in less than two weeks’ time, two bulls are placing their bets behind these drug makers.
Eleven Biotherapeutics Inc (NASDAQ:EBIO) shares are jumping up like wildfire today on back of an encouraging Phase 3 trial data preview in bladder …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) wholly owned subsidiary Salix is fostering a new two-way conversation between health care providers and irritable bowel syndrome …